We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Contrast Agent Enables Low-Dose X-Ray Joint Imaging

By MedImaging International staff writers
Posted on 10 Apr 2026
Image: Ambika Bajpayee and her team at Northeastern developed a patented contrast agent 100 times more efficient than current options (photo courtesy of Ruby Wallau/Northeastern University)
Image: Ambika Bajpayee and her team at Northeastern developed a patented contrast agent 100 times more efficient than current options (photo courtesy of Ruby Wallau/Northeastern University)

X-ray imaging offers limited visualization of soft tissues like cartilage, complicating evaluation of joint pain and degenerative disease. Clinicians often rely on joint-space narrowing as a proxy for cartilage loss, which can be imprecise. Iodine-based contrast agents help but require larger volumes and may pose risks for patients with kidney disease. To help address this challenge, researchers have developed a positively charged contrast agent designed to improve X‑ray visualization of cartilage.

Developed at Northeastern University under the leadership of Ambika Bajpayee, an associate professor of bioengineering, the agent is engineered to leverage the inherent negative charge of soft tissues. The team recently secured a patent for its cationic design, which targets cartilage through electrostatic attraction. By binding to the tissue rather than diffusing away, the agent is designed to improve retention at the site of interest and enable clearer assessment of joint structures using standard radiography.

Soft tissues carry net negative charges due to molecules such as proteins and cell membranes. In cartilage, fixed negative charges also contribute substantially to mechanical properties, supporting restoration of shape after load-bearing. A positively charged contrast agent is drawn into these tissues, where it accumulates and remains available for X‑ray detection more effectively than conventional agents.

The approach aims to address two clinical limitations of current arthrography: poor retention in cartilage because of low perfusion and the need for relatively high injected volumes. According to the developers, imaging with the new method can be performed using approximately 40 times less contrast than usual. The injected agent is absorbed into the joint over about two hours, and it is expected to break down in the body after roughly 24 hours, although additional testing is needed.

Initial studies were conducted in mice, and evaluation in human subjects is anticipated next. If validated clinically, the method could refine radiographic assessment of arthritis by directly enhancing visualization of cartilage rather than relying solely on joint-space measurements.

Related Links
Northeastern University

Diagnostic Ultrasound System
DC-80A
Digital Radiography System
DR-300
X-Ray Generator
Advantage Plus Generators
Medical Radiographic X-Ray Machine
TR30N HF

Channels

General/Advanced Imaging

view channel
Image: The study developed a marker based on the analysis of routine CT scans of gastric cancer patients treated at UNICAMP. Higher radiodensity values for adipose tissue are linked to a worse prognosis. In contrast, higher values for muscle are linked to a more favorable outcome (Photo courtesy of FCM-UNICAMP)

CT-Derived Biomarker Predicts Outcomes in Gastric Cancer

Gastric cancer, also known as stomach cancer, is the fifth most common malignancy worldwide and often shows heterogeneous outcomes even within the same stage. Prognostic estimates typically rely on tumor-centric... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.